Biotheranostics, Inc., announces the launch of its Not Another Minute campaign, revealing how Breast Cancer Index (BCI) is changing the game for early-stage, hormone receptor-positive (HR+) breast cancer patients. At the 42nd annual San Antonio Breast Cancer Symposium (SABCS) this week, thousands of the nation’s top oncologists, surgeons, and patient advocates will experience the new campaign which focuses on individualized care, patient education, and empowerment.

Not Another Minute encourages physicians, patients, and caregivers to make informed, individualized decisions about extending anti-estrogen treatment after five years. While a small percentage of women diagnosed with HR+, early-stage breast cancer have improved outcomes with longer treatment, nearly 95% of patients do not benefit from continuing anti-estrogen therapy beyond five years, based on results from published extended endocrine therapy trials.1-6 The campaign reinforces that 100% of women deserve to know what is right for them regarding extension of endocrine therapy. Breast Cancer Index is the only commercially-available test that predicts whether a woman is likely to benefit from continuing her anti-estrogen therapy to ten years.

For the thousands of oncologists across the US who have already used Breast Cancer Index to help individualize their patients’ anti-estrogen treatment decisions, Biotheranostics is pleased to introduce a newly designed test report intended to facilitate patient and physician understanding and discussions for joint decision-making.

Lisa Whitmyer, Biotheranostics’ VP of Marketing, shares, “As a breast cancer survivor myself, taking anti-estrogen therapy can be a life-altering five years. The Not Another Minute campaign empowers women to understand whether tolerating an additional five years of therapy will benefit them. We were grateful to be able to incorporate feedback from patients and their providers as we redesigned the report to present the Breast Cancer Index results in a clearer and more meaningful way. We are pleased that so many women have already benefited from including the test in their decision making with their provider.”

Don Hardison, Biotheranostics’ President and CEO adds, “We are thrilled that the reception of the new campaign has been so positive. Not another Minute of taking additional treatment that may not benefit her has resonated for patients who feel the impact of taking a daily pill for the last five years, and for providers, knowing if treatment is benefiting their patient gives them the confidence when prescribing an additional five years of anti-estrogen therapy. We are fortunate to offer the only biomarker that predicts the benefit of extended endocrine therapy.”

References: 1. Davies C, et al. Lancet Oncol. 2013;381: 805-816. 2. Gray R et al. J Clin Oncol 2013; 31: (suppl; abstr 5). 3. Jakesz R, et al. J Natl Cancer Inst. 2007;99: 1845-1853. 4. Goss PE, et al. J Natl Cancer Inst. 2005;97: 1262-1271. 5. Goss PE et al. N Engl J Med. 2003;349. 6. Mamounas EP et al. NSABP B-42. S1-05. SABCS 2016 Dec 7, 2016

About Breast Cancer Index®
Breast Cancer Index is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early-stage, HR+ breast cancer. This breakthrough test helps oncologists and patients navigate the difficult trade-off between taking steps to prevent recurrence of their disease and facing significant side effects and safety challenges related to unnecessary treatment. Breast Cancer Index holds guidelines designation from the American Joint Committee on Cancer for cancer staging based on molecular profile; ASCO, NCCN, European Group on Tumor Markers (EGTM), and St. Gallen to inform the chemotherapy decision; and ASCO and EGTM to inform the extended endocrine treatment dilemma. It is the only validated, commercially available test that provides risk of overall and late distant recurrence and predicts the likelihood of benefit from extended endocrine therapy. For more information, visit

About Biotheranostics
Biotheranostics, Inc. operates a CLIA-certified and CAP-accredited diagnostic laboratory in San Diego, California. Biotheranostics, Inc., is a leading healthcare provider in the oncology field assisting physicians in the treatment of cancer patients. Its suite of proprietary molecular diagnostic tests provides important information to physicians to tailor treatment to individual patients. The company’s Breast Cancer Index® and CancerTYPE ID® tests address a variety of unmet medical needs in the management of cancer patients, and extensive clinical studies have confirmed the accuracy, clinical validity, clinical utility, and cost-effectiveness of the tests. Learn more at

Latest news

VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
July 18, 2023

SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed […]

CurvaFix Closes $39 Million Series C Financing Round Led by MVM Partners and Announces CEO Transition
July 14, 2023

BELLEVUE, Wash.–(BUSINESS WIRE)–CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of […]

Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain
June 7, 2023

ALISO VIEJO, Calif., June 7, 2023 /PRNewswire/ — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for […]

eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023

New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May […]

GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing
March 23, 2023

TEMPE, Ariz., March 23, 2023 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients […]

OSSIO Launches World’s First and Only Non-Permanent Compression Staple
February 7, 2023

OSSIOfiber® Compression Staple Answers Surgeon, Patient Demand in Fastest Growing Product Category in Extremities WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation […]

VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
February 6, 2023

Second Generation GENOSYL® DS is the first and only Inhaled Nitric Oxide delivery system that is FDA-approved for rebreathing anesthesia, […]

VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
January 9, 2023

VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced […]

MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022

BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]

MVM Invests in Ossio
October 18, 2022

Proceeds will be used to strengthen awareness for the patient benefits of bio-integrative OSSIOfiber® implants and accelerate new product platforms into the major […]